. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Cancer Control. 2015 Oct;22(4 0):17–23. doi: 10.1177/107327481502204s04

Table 2.

Frontline Regimens for Chronic Lymphocytic Leukemia

Patient Population	Treatment Options
Patients < 70 years of age, or older patients without significant comorbidities and without del(17p)	Fludarabine + cyclophosphamide + rituximab (FCR) Bendamustine ± rituximab (BR) Fludarabine + rituximab (FR) Pentostatin + cyclophosphamide + rituximab (PCR) Obinutuzumab + chlorambucil Ofatumumab + chlorambucil
Patients ≥ 70 years of age or younger patients with comorbidities without del(17p)	Obinutuzumab + chlorambucil Ofatumumab + chlorambucil Bendamustine ± rituximab (BR) Cyclophosphamide ± rituximab ± corticosteroids Fludarabine ± rituximab (FR) Dose-reduced fludarabine + cyclophosphamide + rituximab (FCR) Chlorambucil ± rituximab
Patients with significant comorbidities who are unable to tolerate purine analogues	Obinutuzumab + chlorambucil Ofatumumab + chlorambucil Chlorambucil ± rituximab
Patients with del(17p)	Ibrutinib Idelalisib + rituximab Clinical trial Alemtuzumab